SCHEMBL29476471

SCHEMBL29476471

N=C(N)NCCC[C@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](N)CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CS)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ C5AR1 P21730 1/20 0.50
▸ CTSL P07711 3/20 0.48
▸ CTSS P25774 3/20 0.48
▸ CTSK P43235 3/20 0.48
▸ CTSH P09668 1/20 0.48
▸ MC4R P32245 2/20 0.48
▸ KISS1R Q969F8 2/20 0.47
▸ IL23R Q5VWK5 4/20 0.47
▸ TUBB4A P04350 1/20 0.46
▸ TUBB P07437 1/20 0.46
▸ TUBA3C P0DPH7 1/20 0.46
▸ TUBA1B P68363 1/20 0.46
▸ TUBA4A P68366 1/20 0.46
▸ TUBB4B P68371 1/20 0.46
▸ TUBB3 Q13509 1/20 0.46
▸ TUBB2A Q13885 1/20 0.46
▸ TUBB8 Q3ZCM7 1/20 0.46
▸ TUBA3E Q6PEY2 1/20 0.46
▸ TUBA1A Q71U36 1/20 0.46
▸ TUBA1C Q9BQE3 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30264960 0.97 CTSL (0.49) C5AR1CTSLCTSSCTSKCTSH
SCHEMBL31555126 0.95 MC4R (0.49) C5AR1MC4RKISS1RTUBB4ATUBB
SCHEMBL29476499 0.94 MC4R (0.50) C5AR1MC4RKISS1RTUBB4ATUBB
SCHEMBL29476617 0.93 MC4R (0.50) C5AR1MC4RKISS1RTUBB4ATUBB
SCHEMBL29476562 0.93 MC4R (0.50) C5AR1MC4RKISS1RTUBB4ATUBB
SCHEMBL30264812 0.93 C5AR1 (0.50) C5AR1MC4RKISS1RIL23RTUBB4A
SCHEMBL30264908 0.93 C5AR1 (0.50) C5AR1MC4RKISS1RIL23RTUBB4A
SCHEMBL29511062 0.92 MC4R (0.51) C5AR1CTSLCTSSCTSKCTSH
SCHEMBL10419744 0.92 C5AR1 (0.51) C5AR1CTSLCTSSCTSKCTSH
SCHEMBL30725663 0.92 MC4R (0.49) C5AR1MC4RKISS1RIL23RTUBB4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4618952-A2 METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST Rhythm Pharmaceuticals, Inc. (US) 2025-09-24 — — EP disclosed
WO-2025106751-A1 COMBINATIONS OF A POTASSIUM CHANNEL ACTIVATOR AND AN MC4R AGONIST AND RELATED METHODS OF USE RHYTHM PHARMACEUTICALS, INC. (US) 2025-05-22 — — WO disclosed
EP-4554607-A2 METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST Rhythm Pharmaceuticals, Inc. (US) 2025-05-21 — — EP disclosed
US-20240182519-A1 MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN IPSEN PHARMA S.A.S. (FR) 2024-06-06 — — US disclosed
WO-2024108198-A2 METHODS OF TREATING OBESITY WITH AN MC4R AGONIST RHYTHM PHARMACEUTICALS, INC. (US) 2024-05-23 — — WO disclosed
WO-2024015880-A2 METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST RHYTHM PHARMACEUTICALS, INC. (US) 2024-01-18 — — WO disclosed
EP-4216979-A1 METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS Rhythm Pharmaceuticals, Inc. (US) 2023-08-02 — — EP disclosed
WO-2022067086-A1 METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS RHYTHM PHARMACEUTICALS, INC. (US) 2022-03-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240182519-A1 MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN MC4R, MC3R, MC1R C5AR1 563/4885CTSL 2524/4885CTSS 2918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback